Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | SHFS 0.1324 -61.39% | XXII 0.1977 -8.34% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | RBNE 0.19 -2.56% | YFOR 0.2236 -1.58% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | TQQQ 66.29 -0.20% | TSLL 9.76 -1.21% | VZ 44.66 -1.19% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | GRAB 2.79 -2.11% | AIOK 12.02 182.82% | SQQQ 39.68 0.20% | ONDS 6.2 2.99% | LABT 0.31 -36.67% | AAPL 347.725 -0.14% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | IREN 24.905 -2.37% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | NFLX 65.85 -1.79% | QID 14.55 0.14% | CLRO 3.25 69.27% | WULF 11.32 0.00%
INInsmed Incorporated logo

Insmed Incorporated (INSM)

NASDAQ Global Select · Currency in USD
$93.39 ▼ -1.67 (-1.76%)
At close: Oct 23, 4:00 PM ET. Market closed.
$93.21 ▼ -0.18 (-0.19%)
Pre-market: Oct 26, 7:15 AM ET

Summary

Previous Close
$95.06
Open
$94.12
Day's Range
$92.63 – $94.63
52 Week Range
$90.39 – $212.75
Volume
3,414,134
Avg. Volume
2,958,237
Market Cap
$20.39B
Beta (5Y Monthly)
0.82
PE Ratio (TTM)
--
EPS (TTM)
-$4.03
Earnings Date
Oct 29, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$193.60

Profile: Insmed Incorporated

Sector
Healthcare
Industry
Biotechnology
Full-time employees
1,664
CEO
William H. Lewis
Website
insmed.com

Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils.

Earnings

Next report: Thu, Oct 29, 2026
EPS estimate -$0.39 · Revenue est. $499.06M
DateEst.Actual
Aug 6, 2026-$0.67-$0.06Beat
May 7, 2026-$0.96-$0.76Beat
Feb 19, 2026-$1.07-$1.54Miss
Oct 30, 2025-$1.33-$1.75Miss
Aug 7, 2025-$1.30-$1.70Miss
May 8, 2025-$1.34-$1.42Miss

Analyst view

Consensus price target
$193.60 ▲ +107.3%
Range $169.00 – $235.00
Rating: Buy
Buy 92% · Hold 6% · Sell 3%

Get free alerts on INSM and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.